title: [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].
abstract: We report a long-term complete response (CR) in a patient with postoperative recurrent breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid. We administered 4 courses of tri-weekly CE (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2) and 12 courses of weekly paclitaxel (80 mg/m2) as adjuvant chemotherapy. However, combination therapy with S-1 and zoledronic acid was started because of the development of bone and pleura metastases. S-1 was administered orally at 100 mg/day everyday for 2 weeks, followed by a 1-week rest interval as 1 course; 4 mg of zoledronic acid was injected every 4 weeks. After 3 cycles of treatment, the patient's tumor marker levels had decreased to normal values, and both the bone and pleura metastases had disappeared. A long-term complete response was obtained as a result of this combination therapy.
authors.affiliation: Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine.
authors.forename: Naruhiko
authors.initials: N
authors.lastname: Mizuta
authors.forename: Koichi
authors.initials: K
authors.lastname: Sakaguchi
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Mizuta
authors.forename: Miho
authors.initials: M
authors.lastname: Ichida
authors.forename: Mahiro
authors.initials: M
authors.lastname: Ohashi
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Umeda
authors.forename: Asako
authors.initials: A
authors.lastname: Nishiyama
authors.forename: Midori
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Ikuya
authors.initials: I
authors.lastname: Fujiwara
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D010094:Oxonic Acid / Q000627:therapeutic use*; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000556:secondary; D005641:Tegafur / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D000077211:Zoledronic Acid
chemical_list: D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004338:Drug Combinations; D007093:Imidazoles; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077211:Zoledronic Acid